SIRT1 and B-cell chronic lymphocytic leukemia: In keeping with the evidence that SIRT1 inactivates TP53 by deacetylating a critical lysine residue at position 382 [39], we demonstrated a significant increase of TP53 acetylation at lys382 upon anti-IgM stimulation of CLL cells.